Kamada (NASDAQ:KMDA) Stock Crosses Above Two Hundred Day Moving Average – What’s Next?

Kamada Ltd. (NASDAQ:KMDA)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.03 and traded as high as $7.85. Kamada shares last traded at $7.63, with a volume of 147,183 shares trading hands.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Kamada in a research note on Friday, January 10th.

Kamada Stock Down 2.6 %

The company’s 50 day moving average price is $6.88 and its 200-day moving average price is $6.03. The stock has a market cap of $438.57 million, a P/E ratio of 27.25, a P/E/G ratio of 0.98 and a beta of 0.99.

Hedge Funds Weigh In On Kamada

Large investors have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,549 shares during the last quarter. Aristides Capital LLC raised its stake in Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after buying an additional 6,850 shares during the last quarter. NewEdge Advisors LLC raised its stake in Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after buying an additional 8,260 shares during the last quarter. JPMorgan Chase & Co. bought a new position in Kamada during the fourth quarter worth $67,000. Finally, Public Employees Retirement System of Ohio bought a new position in Kamada during the third quarter worth $77,000. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.